CGI Holding Supports GeneS: The S100B Protein as a Key to Gut Health

An important discovery in neuroscience and biotechnology comes from the startup GeneS, supported by CGI Holding.
The S100B protein, previously known mainly for its role in the brain as a biomarker in neurological diseases, has now been identified in the gut microbiota, our bacterial flora, where it plays a key regulatory role.
Studies conducted by the Rome-based startup with experts from the University of Rome “Foro Italico”, including Professors Vincenzo Romano Spica and Fabrizio Michetti, have demonstrated the crucial role of S100B in the digestive system. The protein appears to have a regulatory function that could offer new therapeutic possibilities for treating gut dysbiosis and inflammatory diseases such as Crohn's disease.
In particular, the discovery suggests that a targeted diet rich in S100B could help restore balance to the microbiota. Foods such as apples, cow's, goat's and sheep's milk, and breast milk, are rich in this protein, which could become a key ingredient in the future of functional nutrition. In this context, the research opens new possibilities for developing supplements that improve gut health and, indirectly, neurological health.
The importance of S100B extends beyond the gut: the protein is also being studied for its positive effects on the skin, suggesting possible use in cosmetics. . GeneS, which participated in Cosmoprof Worldwide Bologna, the leading international cosmetics trade fair, presented its first line of beauty products based on S100B protein, using natural sources of this substance.
Our support for GeneS research promotes innovation in biotechnology and highlights the importance of the link between nutrition, gut health and physical and mental well-being, opening new opportunities for applications in many areas of medicine and skincare.
